{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"condition":["Unresectable Metastatic Colorectal Cancer","Colorectal Neoplasms","Cancer"],"disease":["Unresectable Metastatic Colorectal Cancer","Colorectal Neoplasms","Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2140917"],"location":["France"],"study_start_month":["5"],"keyword":["OPTIMOX","Colorectal","Unresectable","Metastatic","Aflibercept"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer","description":"Evaluation of feasibility of adding aflibercept to an oxaliplatin-based regimen rather than a continuous administration of chemotherapy until progression, in order to decrease the risk of severe toxicities.","dates":{"creation":"2013-05-15"},"accession":"2140917","cross_references":{"ClinicalTrials___gov":["NCT01802684"],"EU Clinical Trials Register":["2012-003521-25"]}}